Cardinal buys up Alaris shares:
This article was originally published in Clinica
Cardinal Health has completed its tender offer for all outstanding shares of common stock of Alaris Medical Systems. As previously announced, Cardinal purchased the shares at a price of $22.35 each in cash as part of its plan to acquire San Diego, California-based Alaris. The final steps to completing the merger - in which the developer of needle-free valves and systems will become a wholly-owned Cardinal subsidiary - is going ahead despite the dark cloud of litigation hanging over Alaris. At the end of last month, ICU Medical had filed a patent lawsuit against San Diego, California-based Alaris concerning the latter's SmartSite and SmartSite Plus needle-free valves and systems (see Clinica No 1113, p 12).
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.